JP2019518756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518756A5 JP2019518756A5 JP2018564884A JP2018564884A JP2019518756A5 JP 2019518756 A5 JP2019518756 A5 JP 2019518756A5 JP 2018564884 A JP2018564884 A JP 2018564884A JP 2018564884 A JP2018564884 A JP 2018564884A JP 2019518756 A5 JP2019518756 A5 JP 2019518756A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- former
- sodium benzoate
- disorder
- benzoate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010234 sodium benzoate Nutrition 0.000 claims 15
- 239000004299 sodium benzoate Substances 0.000 claims 15
- -1 sodium benzoate compound Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 239000002904 solvent Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 5
- 238000003756 stirring Methods 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 201000001420 glucose metabolism disease Diseases 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 239000012047 saturated solution Substances 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010001954 Amnestic disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 206010003484 Asperger's disease Diseases 0.000 claims 1
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006093 Closed Head Injury Diseases 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010024094 Learning disease Diseases 0.000 claims 1
- 206010061284 Mental disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010034721 Personality disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010043835 Tic disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000007185 autism spectrum disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000008839 post-traumatic stress disease Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
Claims (27)
- 前記安息香酸ナトリウム化合物及び前記共形成剤が、1:10〜10:1の分子比率の範囲で前記共結晶中に存在する、請求項1に記載の共結晶。
- Lが、C=C又はC=C-C=Cであり、及びAが、C1-C6アルキル、アリール、又はヘテロアリールである、請求項1又は2に記載の共結晶。
- Lが、C=C-C=Cであり、Aが、メチルであり、及びXが、Oである、請求項3に記載の共結晶。
- 前記安息香酸ナトリウム化合物及び前記共形成剤が、1:2の分子比率で前記共結晶中に存在する、請求項4に記載の共結晶。
- 前記安息香酸ナトリウム化合物及び前記共形成剤が、1:1の分子比率で前記共結晶中に存在する、請求項4に記載の共結晶。
- Lが、C=Cであり、Aが、フェニルであり、及びXが、Oである、請求項3に記載の共結晶。
- 前記安息香酸ナトリウム化合物及び前記共形成剤が、1:2の分子比率で前記共結晶中に存在する、請求項10に記載の共結晶。
- Lが、不存在であり、Aが、ピリジルであり、及びXが、Oである、請求項3に記載の共結晶。
- 前記安息香酸ナトリウム化合物及び前記共形成剤が、1:1の分子比率で前記共結晶中に存在する、請求項13に記載の共結晶。
- 有効量の請求項1〜15の何れか1項に記載の共結晶及び担体を含む、組成物。
- 前記組成物が、医薬組成物、栄養補助組成物、健康食品、又は医療用食品である、請求項16に記載の組成物。
- 治療有効量の請求項1〜15の何れか1項に記載の共結晶を含む対象の精神神経疾患を治療する又はそのリスクを低減させる組成物。
- 前記精神神経疾患が、統合失調症、精神障害、アルツハイマー病、認知症、軽度認知障害、良性健忘症、閉鎖性頭部外傷、自閉症スペクトル障害、アスペルガー症候群、注意欠陥・多動性障害、強迫性障害、チック症、幼年期学習障害、月経前症候群、うつ病、双極性障害、不安症、心的外傷後ストレス障害、慢性疼痛、摂食障害、依存症、パーソナリティ障害、パーキンソン病、ハンチントン病及び筋萎縮性側索硬化症、からなる群から選択される、請求項18に記載の組成物。
- 治療有効量の請求項1〜15の何れか1項に記載の共結晶を含むグルコース若しくは脂質代謝障害を治療する又はそのリスクを低減させる組成物。
- 前記グルコース又は脂質代謝障害が、肥満、糖尿病、高コレステロール血症、高血圧、及び高脂血症、からなる群から選択される、請求項20に記載の組成物。
- 共結晶を調製する方法であって、当該方法が、
(i)約40〜110℃の温度で、前記安息香酸ナトリウム化合物及び前記共形成剤を溶媒中で混合し、飽和溶液を形成する工程、ここで、前記安息香酸ナトリウム化合物及び前記共形成剤が、1:10〜10:1のモル比率であり;
(ii)約70〜150℃の温度で前記溶液を加熱及び撹拌し、前記共結晶を形成させる工程; 及び
(iii)(ii)で形成された前記共結晶を回収する工程、
を含む、請求項1〜15の何れか1項に記載の共結晶の調製方法。 - 工程(i)が、前記安息香酸ナトリウム化合物及び前記共形成剤に前記溶媒を滴下し、形成された混合物を撹拌することによって行われ、このような方法で前記安息香酸ナトリウム化合物及び前記共形成剤を前記溶媒中に溶解させる、請求項22に記載の方法。
- (i)約40〜110℃の温度で、前記安息香酸ナトリウム化合物及び前記共形成剤を溶媒中で混合し、飽和溶液を形成する工程、ここで、前記安息香酸ナトリウム化合物及び前記共形成剤が、1:10〜10:1のモル比率であり;
(ii)前記溶液を室温まで冷却する工程;
(iii)前記安息香酸ナトリウム化合物及び前記共形成剤の種(seed)共結晶を、(ii)の前記溶液に加えて混合物を形成する工程;
(iv)前記混合物を、室温に静置し、前記共結晶を形成させる工程; 及び
(v)(iv)で形成された前記共結晶を回収する工程、
を含む、請求項1〜15の何れか1項に記載の共結晶の調製方法。 - 工程(i)が、前記安息香酸ナトリウム化合物及び前記共形成剤に前記溶媒を滴下し、形成された混合物を撹拌することによって行われ、このような方法で前記安息香酸ナトリウム化合物及び前記共形成剤を前記溶媒中に溶解させる、請求項24に記載の方法。
- (i)請求項1〜15の何れか1項に記載の共結晶を提供する工程;
(ii)約35〜100℃の範囲の温度で、前記共結晶を溶媒に溶解して溶液を形成する工程;
(iii)前記溶液を約40〜110℃の温度で第1の期間撹拌し、前記共結晶を形成させる工程; ここで、前記第1の期間は、約1〜10日であり; 及び
(iv)前記共結晶を回収する工程、
を含む、請求項1〜15の何れか1項に記載の共結晶を調製するための方法。 - 工程(iii)に続いて、前記溶液を約40〜110℃の温度で第2の期間撹拌することをさらに含み、ここで、第2の期間は、約1〜10日である、
請求項26に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662349578P | 2016-06-13 | 2016-06-13 | |
US62/349,578 | 2016-06-13 | ||
PCT/CN2017/088045 WO2017215593A1 (en) | 2016-06-13 | 2017-06-13 | Co-crystals of sodium benzoate and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019518756A JP2019518756A (ja) | 2019-07-04 |
JP2019518756A5 true JP2019518756A5 (ja) | 2019-10-17 |
JP6958922B2 JP6958922B2 (ja) | 2021-11-02 |
Family
ID=60663996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018564884A Active JP6958922B2 (ja) | 2016-06-13 | 2017-06-13 | 安息香酸ナトリウムの共結晶及びその使用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US11008277B2 (ja) |
EP (1) | EP3468944B1 (ja) |
JP (1) | JP6958922B2 (ja) |
KR (1) | KR102403048B1 (ja) |
CN (1) | CN109563018A (ja) |
CA (1) | CA3027297A1 (ja) |
DK (1) | DK3468944T3 (ja) |
ES (1) | ES2936094T3 (ja) |
FI (1) | FI3468944T3 (ja) |
IL (1) | IL263492B (ja) |
MX (1) | MX2018015397A (ja) |
TW (1) | TWI671287B (ja) |
WO (1) | WO2017215593A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI736635B (zh) | 2016-06-13 | 2021-08-21 | 心悅生醫股份有限公司 | 苯甲酸鋰之共晶及其用途 |
WO2019103597A1 (en) | 2017-11-22 | 2019-05-31 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3498989A (en) | 1969-04-16 | 1970-03-03 | American Home Prod | Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof |
US3870715A (en) | 1972-03-09 | 1975-03-11 | Nikolaus R Hansl | Substituted amino ethyl meta benzoic acid esters |
US4041174A (en) | 1974-08-16 | 1977-08-09 | Rom-Amer Pharmaceuticals, Ltd. | Method of treating depression |
US4731379A (en) * | 1983-12-07 | 1988-03-15 | H.S.C. Corporation | Flea eradicator |
US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
GB8819494D0 (en) | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
CA2058455A1 (en) * | 1990-12-21 | 1992-06-22 | Mark W. Collison | Synergistic effect of lantibiotics in combination with selected agents against gram positive bacteria |
CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
FR2700117B1 (fr) | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
DE4340273A1 (de) | 1993-11-26 | 1995-06-01 | Karla Dr Lehmann | Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
US5441981A (en) * | 1994-01-27 | 1995-08-15 | Buckman Laboratories International, Inc. | Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid |
US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
US6146847A (en) * | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
DE19925425A1 (de) * | 1999-06-02 | 2000-12-07 | Wessollek Heimo | Mittel zur Entkeimung bzw. keimreduzierenden Gestaltung von Reinigungs-, Sanitär- und Toilettenartikeln sowie kosmetischen Artikeln, Körperpflegeartikeln und dergleichen verkeimungsgefährdeten Gegenständen |
WO2001041707A2 (en) | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
HUP0302874A2 (hu) | 2000-08-14 | 2003-12-29 | Teva Pharmaceutical Industries Ltd. | Eljárás risperidon előállítására |
US20030185754A1 (en) | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
CN1568370A (zh) | 2001-01-16 | 2005-01-19 | 根瑟特公司 | 用d-氨基酸氧化酶和d-天冬氨酸氧化酶拮抗剂治疗中枢神经系统障碍 |
US20100311701A1 (en) | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
MXPA04006900A (es) | 2002-10-24 | 2004-10-15 | Merz Pharma Gmbh & Co Kgaa | Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa. |
CA2514092C (en) * | 2003-01-21 | 2013-03-19 | S.S.C.I., Inc. | Novel cocrystallization of hydrochloric acid salt of an active agent |
CA2798615A1 (en) | 2003-01-21 | 2004-08-05 | Aptuit (West Lafayette), Llc | Novel cocrystallization of hydrochloric acid salt of an active agent |
WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
CA2527284A1 (en) | 2003-06-02 | 2005-01-06 | Laurent Lecanu | Methods and compositions for modulating serum cortisol levels |
CN102010382A (zh) | 2003-12-29 | 2011-04-13 | 塞普拉科公司 | 苯并[d]异噁唑-3-醇DAAO抑制剂 |
AR047459A1 (es) | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
WO2005079851A2 (en) | 2004-02-18 | 2005-09-01 | Sepracor, Inc. | Dopamine-agonist combination therapy with sedatives for improving sleep quality |
EP1742535A4 (en) | 2004-05-06 | 2008-10-15 | Cydex Pharmaceuticals Inc | MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN |
JP5017103B2 (ja) | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 薬剤共結晶組成物および関連した使用方法 |
WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
CA2505808A1 (en) * | 2005-05-02 | 2006-11-02 | Julie Danielle Globus | Niacin used as oral supplementation for the treatment of psychosis and/or schizophrenia in humans |
WO2006129160A2 (en) | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
US20110045065A1 (en) | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
GB0603181D0 (en) | 2006-02-17 | 2006-03-29 | Merck Sharp & Dohme | Treatment of neurodegenerative and psychiatric diseases |
US20080045547A1 (en) * | 2006-07-07 | 2008-02-21 | Lippa Arnold S | Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use |
US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
WO2008034087A2 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
US20100204204A1 (en) * | 2007-06-06 | 2010-08-12 | University Of South Florida | Nutraceutical co-crystal compositions |
US8071143B2 (en) * | 2008-04-02 | 2011-12-06 | Brandeis University | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
US20130338199A1 (en) | 2008-07-11 | 2013-12-19 | Uday Saxena | Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease |
GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
WO2010027921A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ppar活性化剤 |
ES2615884T3 (es) | 2009-01-20 | 2017-06-08 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Ácido sórbico y benzoico y sus derivados que aumentan la actividad de un neurofármaco |
ES2882010T3 (es) | 2010-07-23 | 2021-11-30 | Gruenenthal Gmbh | Sales o cocristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol |
EP2688575B1 (en) | 2011-03-24 | 2016-03-23 | University of South Florida | Lithium compositions |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
PH12012000132A1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
US9120766B2 (en) * | 2011-10-21 | 2015-09-01 | Amri Ssci, Llc | Methods of making cocrystals |
BR112014024276A2 (pt) * | 2012-03-30 | 2017-08-08 | Nuformix Ltd | composições de tranilast e co-cristais |
HRP20220289T1 (hr) | 2013-04-19 | 2022-05-27 | University Of South Florida | Organski anion litij-ionski kokristalni spojevi i sastavi |
WO2014178040A1 (en) | 2013-04-29 | 2014-11-06 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
PL3424920T3 (pl) * | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
HUE048488T2 (hu) * | 2013-12-13 | 2020-07-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával |
DE212014000063U1 (de) * | 2014-03-24 | 2015-10-12 | China Medical University | Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung |
CN103992320A (zh) * | 2014-05-26 | 2014-08-20 | 南京工业大学 | 一种混悬结晶制备药物共晶的方法 |
US9896429B2 (en) * | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
CN113816940A (zh) * | 2014-05-27 | 2021-12-21 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体络合物 |
KR20170083146A (ko) * | 2014-11-19 | 2017-07-17 | 러쉬 유니버시티 메디컬 센터 | 리소좀 질환들의 치료를 위한 방법들 및 조성물들 |
RU2582962C1 (ru) | 2014-12-23 | 2016-04-27 | Ольга Алексеевна Громова | Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты) |
TWI736635B (zh) * | 2016-06-13 | 2021-08-21 | 心悅生醫股份有限公司 | 苯甲酸鋰之共晶及其用途 |
CA3022020A1 (en) | 2016-06-14 | 2017-12-21 | Aemerge Llc | Hydrocarbon recycling of carbonizer hot gases |
US10064833B2 (en) * | 2016-08-04 | 2018-09-04 | Syneurx International (Taiwan) Corp. | Compositions containing benzoate compound and tannic acid for treating central nervous system disorders |
US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
US9877942B1 (en) * | 2017-02-13 | 2018-01-30 | Syneurx International (Taiwan) Corp. | Co-crystals of substituted glycine and uses thereof |
US20190076472A1 (en) * | 2017-09-14 | 2019-03-14 | CT Development One, LLC | Hyperammonemia therapy for children suffering from urea cycle disorders |
US10098861B1 (en) * | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
-
2017
- 2017-06-13 CA CA3027297A patent/CA3027297A1/en active Pending
- 2017-06-13 TW TW106119576A patent/TWI671287B/zh active
- 2017-06-13 ES ES17812704T patent/ES2936094T3/es active Active
- 2017-06-13 JP JP2018564884A patent/JP6958922B2/ja active Active
- 2017-06-13 EP EP17812704.9A patent/EP3468944B1/en active Active
- 2017-06-13 KR KR1020197000864A patent/KR102403048B1/ko active IP Right Grant
- 2017-06-13 DK DK17812704.9T patent/DK3468944T3/da active
- 2017-06-13 MX MX2018015397A patent/MX2018015397A/es unknown
- 2017-06-13 US US16/309,349 patent/US11008277B2/en active Active
- 2017-06-13 WO PCT/CN2017/088045 patent/WO2017215593A1/en unknown
- 2017-06-13 FI FIEP17812704.9T patent/FI3468944T3/fi active
- 2017-06-13 CN CN201780047165.6A patent/CN109563018A/zh active Pending
-
2018
- 2018-12-04 IL IL263492A patent/IL263492B/en unknown
-
2021
- 2021-05-03 US US17/306,005 patent/US11731928B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2898315T3 (es) | Preparación de nicotina racémica mediante reacción de nicotinato de etilo con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores | |
US9701702B2 (en) | Metathesis catalysts and methods thereof | |
JP2019518756A5 (ja) | ||
US8546500B2 (en) | Complexes for use in metathesis reactions | |
JP2016040271A5 (ja) | ||
RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
JP2006151999A5 (ja) | ||
JP2009525312A5 (ja) | ||
JP2019518757A5 (ja) | ||
RU2019128576A (ru) | Сокристаллы замещенных глициновых соединений и их применение | |
JP2020507567A5 (ja) | ||
JP2019523279A5 (ja) | ||
RU2018146423A (ru) | Сокристаллы бензоата лития и их применения | |
CN105820184A (zh) | 一种4-苯氧基苯硼酸的制备方法 | |
JP2019529553A5 (ja) | ||
JPWO2013147216A1 (ja) | (2−ヘテロアリールアミノ)コハク酸誘導体 | |
JP2015168671A (ja) | 有機ホウ素化合物及びその製造方法 | |
RU2019100436A (ru) | Сокристаллы бензоата натрия и их применения | |
JP2018090594A (ja) | ロジウム触媒及びアミン化合物の製造法 | |
CA2979121A1 (en) | Stereoselective synthesis of enantiomers of 8-hydroxyquinoline derivati ves | |
US11020730B2 (en) | Halogen-containing metathesis catalysts and methods thereof | |
CN101910176A (zh) | N-苯基咪唑并[1,2-a]吡啶-2-甲酰胺衍生物,它们的制备和它们的治疗应用 | |
El-Kadri et al. | Synthesis, structure, properties, volatility, and thermal stability of molybdenum (II) and tungsten (II) complexes containing allyl, carbonyl, and pyrazolate or amidinate ligands | |
JP2017514867A5 (ja) | ||
JP2021098666A (ja) | gem−ジフルオロシクロプロペンテトラフルオロスルファニルアレーン化合物 |